Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? - Rickey J. White, Jr. | RJW™
28649
post-template-default,single,single-post,postid-28649,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-16.3,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive
 

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

11 Nov Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Posted at 08:00h in Popular Newsfeed by
0 Likes

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Source: Entrepreneur.com Lastest News

Tags:
No Comments

Sorry, the comment form is closed at this time.